Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB

(UCB)
  Report
Real-time Quote. Real-time Euronext Bruxelles - 01/18 10:20:22 am
85.78 EUR   -1.22%
01/15UCB : announces changes on Board of Directors
PU
01/09UCB : Disposals of own shares
PU
01/07WERNER LANTHALER : Evotec to attend upcoming investor conferences
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
01/12/2021 01/13/2021 01/14/2021 01/15/2021 01/18/2021 Date
85.84(c) 87.78(c) 88.1(c) 86.84(c) 85.78 Last
194 789 312 850 267 100 294 911 100 107 Volume
-0.88% +2.26% +0.36% -1.43% -1.22% Change
More quotes
Financials
Sales 2020 5 201 M 6 272 M 6 272 M
Net income 2020 755 M 911 M 911 M
Net Debt 2020 1 376 M 1 659 M 1 659 M
P/E ratio 2020 22,3x
Yield 2020 1,46%
Sales 2021 5 463 M 6 588 M 6 588 M
Net income 2021 908 M 1 095 M 1 095 M
Net Debt 2021 630 M 760 M 760 M
P/E ratio 2021 18,3x
Yield 2021 1,55%
Capitalization 16 408 M 19 838 M 19 785 M
EV / Sales 2020 3,42x
EV / Sales 2021 3,12x
Nbr of Employees 7 600
Free-Float 62,2%
More Financials
Company
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. 
More about the company
Notations Surperformance© of UCB
Trading Rating : Investor Rating :
More Ratings
All news about UCB
01/15UCB : announces changes on Board of Directors
PU
01/09UCB : Disposals of own shares
PU
01/07WERNER LANTHALER : Evotec to attend upcoming investor conferences
DJ
01/05PRESS RELEASE : Evotec achieves milestone in its neurodegeneration collaboration..
DJ
2020UCB : S.A. - Disposals of own shares
AQ
2020PRESS RELEASE : Evotec partners with alloy therapeutics to expand its antibody d..
DJ
2020UCB : Disposals of own shares
PU
2020PRESS RELEASE : Evotec achieves key milestones in its collaboration with bristol..
DJ
2020UCB : Employee Engagement and Mobility Drives Better Patient Outcomes
PU
2020UCB : Disposals of own shares
PU
2020UCB : Scientific Collaboration and Innovation in Hematology
PU
2020Amgen Inc. - World's Leading Life Science Companies Now Enrolling COMMUNITY, ..
AQ
2020Takeda Pharmaceutical Company Limited - World's Leading Life Science Companie..
AQ
2020COVID R&D Alliance launches trial of Amgen, UCB, Takeda drugs
RE
2020Covid r&d alliance launches trial of amgen, ucb, takeda drugs for hospitalize..
RE
More news
News in other languages on UCB
01/08Donald Trump s'efface (pour le moment)
01/08AVIS D'ANALYSTES DU JOUR : AB Inbev, BE Semi, Danone, Elis, Gecina, Idorsia, Ips..
2020TOUR DU MONDE DES INDICES : l’Aristocratie souffre sur le S&P500, la Santé sauve..
2020Goldman belässt Roche auf 'Conviction Buy List'
2020UCB : la FDA et l'EMA vont examiner le bimekizumab
More news
Analyst Recommendations on UCB
More recommendations
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | MarketScreener
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 109,59 €
Last Close Price 86,84 €
Spread / Highest target 55,5%
Spread / Average Target 26,2%
Spread / Lowest Target -4,42%
EPS Revisions
Managers and Directors
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Sandrine Dufour Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Dhavalkumar Patel Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
UCB2.79%19 838
CSL LIMITED-5.62%93 853
SAMSUNG BIOLOGICS CO.,LTD.-2.66%48 243
BIOGEN INC.12.65%42 447
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.-2.71%35 533
ALEXION PHARMACEUTICALS, INC.0.29%34 293